However, Phase II trials in ovarian cancer, including resistant cases, have demonstrated a diverse range of responses to mTOR inhibitors, such as temsirolimus [24], indicating that better criteria are necessary to determine which patients are the best candidates for mTOR inhibitors. The gene discussed is MTOR; the disease is ovarian carcinoma.